Verge Genomics

Verge Genomics launched with a deliberately narrow MVP: a machine learning pipeline that analyzed their proprietary patient genomics dataset to identify novel drug targets for ALS and Parkinson's disease. ​​‌‌‌‌‌‌‌​‌‌​​‌​​​​​​‌‌​‌‌‌​​​‌‌Rather than building a full drug development platform, they shipped target identification capabilities within months, deliberately excluding wet lab validation, clinical trial infrastructure, and multi-disease coverage. This constraint forced ruthless focus on their core differentiation—mining human tissue data through AI to surface targets competitors missed. The execution paid dividends quickly. Pharma partnerships validated the approach within the first year, with major companies licensing their AI-discovered targets. This early traction proved their core hypothesis: human genomics data plus machine learning could compress target discovery timelines from years to months. By staying lean on infrastructure and shipping their strongest capability first, Verge demonstrated defensible value before expanding into full drug development, turning their MVP constraints into competitive advantages that attracted both capital and partnerships.